A Systematic Search and Methodological Review of Economic Models of Analgesics for Chronic Pain.

References Annemans, L., K. Caekelbergh, B. Morlion, G. Hans, C. P. De and S. Marbaix (2008). "A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain." Acta Clinica Belgica 63(3): 170-178, Armstrong, E. P., D. C. Malone, B. McCarberg, C. J. Panarites and S. V. Pham (2011). "Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. [Review]." Current Medical Research & Opinion 27(5): 939-950. Beard, S. M., L. McCrink, T. K. Le, A. Garcia-Cebrian, B. Monz and R. A. Malik (2008). "Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK." Current Medical Research & Opinion 24(2): 385-399, Breivik, H., E. Eisenberg and O. Tony (2013). "The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care." BMC public health 13(1): 1229, Cepeda, M. S. and J. T. Farrar (2006). "Economic evaluation of oral treatments for neuropathic pain." Journal of Pain 7(2): 119-128, Coluzzi, F. and M. Ruggeri (2014). "Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain." Curr Med Res Opin 30(6): 1139-51. Dakin, H., M. Nuijten, H. Liedgens and B. P. Nautrup (2007). "Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom." Clinical Therapeutics 29(7): 1491-1507. de Salas-Cansado, M., C. Perez, M. T. Saldana, A. Navarro, F. J. Gonzalez-Gomez, L. Ruiz and J. Rejas (2012). "An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings." Primary care diabetes 6(4): 303-312, Dunlop, W., R. Uhl, I. Khan, A. Taylor and G. Barton (2012). "Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis (Structured abstract)." Journal of Medical Economics 15: 564-575, Frei, A., S. Andersen, P. Hole and N. H. Jensen (2003). "A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain." Journal of Pain and Palliative Care Pharmacotherapy 17(2): 2003, Gordon, J., S. Lister, M. Prettyjohns, P. McEwan, A. Tetlow and Z. Gabriel (2012). "A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain." Journal of Medical Economics 15(2): 207218. Hass, B., J. Lungershausen, N. Hertel, N. B. Poulsen, W. Kotowa and H. Liedgens (2009). "Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach." European Journal of Health Economics 10(3): 309-321. Ikenberg, R., N. Hertel, R. A. Moore, M. Obradovic, G. Baxter, P. Conway and H. Liedgens (2012). "Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.[Erratum appears in J Med Econ. 2012;15(6):1216]." Journal of Medical Economics 15(4): 724-736 National Institute for Health and Care Excellence (NICE). (2012, 2012-05-23). "CG140 Opioids in palliative care: full guideline." from http://guidance.nice.org.uk/CG140/Guidance/pdf/English . National Institute for Health and Care Excellence (NICE). (2013, 2013-11-20). "NICE guideline CG173: Neuropathic pain pharmacological management." from http://guidance.nice.org.uk/CG173/NICEGuidance/pdf/English Figure 1: Proposed model structure for Non-Neuropathic Chronic Pain Though the care pathway for chronic pain may be complex and heterogeneous, data limitations may preclude meaningful benefit from discrete event or discrete individual simulation approaches, and the proposed model is a Markov state-transition model. The model depicted in Figure 1 is designed with the flexibility to test the sensitivity of model outcomes to the inclusion/exclusion of 3rd-line treatment options and adjustments to costs and outcomes in initial treatment weeks attributable to dose titration.